68Ga-DOTATATE PET/CT检出抗GD2免疫治疗后儿童神经母细胞瘤患者的肥厚性骨关节病
本文报告一例5岁高危神经母细胞瘤男童,在抗GD2免疫治疗后作为临床试验的一部分接受68Ga-DOTATATE PET/CT评估疗效。显像显示双侧股骨与胫骨对称性摄取增高伴骨膜增生,18F-MFBG PET/CT未见异常摄取且未发现转移,最终诊断为肥厚性骨关节病。提示该病可作为抗GD2治疗后的罕见并发症,并可由68Ga-DOTATATE PET/CT检出。
要点
- 抗GD2免疫治疗后出现双侧股骨、胫骨对称性摄取增高伴骨膜增生时,应想到肥厚性骨关节病。
- 68Ga-DOTATATE PET/CT可显示肥厚性骨关节病的骨摄取改变,而18F-MFBG PET/CT未见异常摄取。
- 本例未发现转移,提示骨摄取改变未必代表肿瘤骨转移。
核心结论
- 肥厚性骨关节病可作为抗GD2免疫治疗后的罕见并发症出现,并可被68Ga-DOTATATE PET/CT检出。
研究设计与样本
- 个案报道:1例5岁高危神经母细胞瘤男童,在抗GD2免疫治疗后作为临床试验的一部分行68Ga-DOTATATE PET/CT评估治疗反应。
主要发现
- 68Ga-DOTATATE PET/CT显示双侧股骨与胫骨对称性摄取增高伴骨膜增生。
- 18F-MFBG PET/CT未见异常摄取,未发现转移。
- 最终诊断为肥厚性骨关节病。
临床怎么用
- 儿童神经母细胞瘤患者抗GD2免疫治疗后行68Ga-DOTATATE PET/CT时,若见双侧长骨对称性摄取增高伴骨膜增生,应鉴别肥厚性骨关节病而非骨转移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 5-year-old boy with high-risk neuroblastoma underwent 68Ga-DOTATATE PET/CT as part of a clinical trial to assess treatment response after anti-GD2 immunotherapy. The scan showed symmetric increased uptake in bilateral femora and tibiae with periostosis. 18F-MFBG PET/CT revealed no abnormal uptake, and no metastasis was found. The diagnosis was hypertrophic osteoarthropathy. This case demonstrates that hypertrophic osteoarthropathy can occur as a rare complication after anti-GD2 therapy and can be detected by 68Ga-DOTATATE PET/CT.
引用
- Li S, Wang X, Zhang K, et al. 68Ga-DOTATATE PET/CT Detection of Hypertrophic Osteoarthropathy in a Pediatric Patient With Neuroblastoma Following Anti-GD2 Immunotherapy. Clin Nucl Med. 2026. PMID: 42853990. doi:10.1097/RLU.0000000000006677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。